TY - JOUR
T1 - Incidence of severe renal dysfunction among individuals taking warfarin and implications for non–vitamin K oral anticoagulants
AU - Fanola, Christina L.
AU - Mooney, Deirdre
AU - Cowan, Andrew J.
AU - Ko, Darae
AU - Sisson, Emily K.
AU - Henault, Lori E.
AU - Tripodis, Yorghos
AU - Hylek, Elaine M.
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Background The purpose of this study is to assess incidence and risk factors for severe renal dysfunction in patients requiring oral anticoagulation to help guide initial drug choice and provide a rational basis for interval monitoring of renal function for patients prescribed non–vitamin K oral anticoagulants. Methods Patients on warfarin for atrial fibrillation or venous thromboembolism were consecutively enrolled from January 2007 to December 2010. Baseline kidney function was assessed, and patients were followed to their first decline of kidney function to creatinine clearance <30 mL/min. Multivariate regression assessed independent risk factors for the primary outcome. Severe renal impairment based on baseline kidney function was assessed by Kaplan-Meier analyses. Results Of 787 patients identified, 34 were excluded for baseline CrCl <30 mL/min. The mean age was 71 years, and 74% and 31% had hypertension and diabetes mellitus, respectively. At baseline, 23% (n = 174) had moderate chronic kidney disease (CKD) (CrCl 30-59 mL/min), whereas 31% had mild CKD (CrCl 60-89 mL/min). Severe renal impairment occurred in 92 patients (12%), 25% of which was seen within 5.3 months. Of those with baseline stage 3 CKD, 37% developed severe renal impairment. Stage 3 CKD conferred a 14-fold increased risk in the development of severe renal dysfunction (odds ratio 14.5, 95% CI 6.7-31.3, P < .001). Coronary artery disease was also associated with severe renal impairment (odds ratio 2.2, 95% CI 1.3-3.8, P = .004). Conclusions Acute and chronic renal dysfunction is common among individuals requiring long-term anticoagulant therapy. Patients with moderate chronic kidney disease and coronary artery disease are at the highest short-term risk of developing severe renal impairment. More frequent monitoring of these patients is warranted.
AB - Background The purpose of this study is to assess incidence and risk factors for severe renal dysfunction in patients requiring oral anticoagulation to help guide initial drug choice and provide a rational basis for interval monitoring of renal function for patients prescribed non–vitamin K oral anticoagulants. Methods Patients on warfarin for atrial fibrillation or venous thromboembolism were consecutively enrolled from January 2007 to December 2010. Baseline kidney function was assessed, and patients were followed to their first decline of kidney function to creatinine clearance <30 mL/min. Multivariate regression assessed independent risk factors for the primary outcome. Severe renal impairment based on baseline kidney function was assessed by Kaplan-Meier analyses. Results Of 787 patients identified, 34 were excluded for baseline CrCl <30 mL/min. The mean age was 71 years, and 74% and 31% had hypertension and diabetes mellitus, respectively. At baseline, 23% (n = 174) had moderate chronic kidney disease (CKD) (CrCl 30-59 mL/min), whereas 31% had mild CKD (CrCl 60-89 mL/min). Severe renal impairment occurred in 92 patients (12%), 25% of which was seen within 5.3 months. Of those with baseline stage 3 CKD, 37% developed severe renal impairment. Stage 3 CKD conferred a 14-fold increased risk in the development of severe renal dysfunction (odds ratio 14.5, 95% CI 6.7-31.3, P < .001). Coronary artery disease was also associated with severe renal impairment (odds ratio 2.2, 95% CI 1.3-3.8, P = .004). Conclusions Acute and chronic renal dysfunction is common among individuals requiring long-term anticoagulant therapy. Patients with moderate chronic kidney disease and coronary artery disease are at the highest short-term risk of developing severe renal impairment. More frequent monitoring of these patients is warranted.
UR - http://www.scopus.com/inward/record.url?scp=85007502669&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85007502669&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2016.08.017
DO - 10.1016/j.ahj.2016.08.017
M3 - Article
C2 - 28224930
AN - SCOPUS:85007502669
SN - 0002-8703
VL - 184
SP - 150
EP - 155
JO - American Heart Journal
JF - American Heart Journal
ER -